Global
# |
Name |
Revenue Per Share |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 68,343.25
|
Sept. 30, 2023 | USD 4.62 | -0.22% |
|
United States |
|
2 |
USD 9,643.47
|
Dec. 31, 2023 | USD 20.08 K | 0.04% |
|
France |
|
3 |
USD 1,980.50
|
Dec. 31, 2023 | USD 2.82 | -2.42% |
|
Canada |
|
4 |
USD 1,308.96
|
Dec. 31, 2023 | USD 1.16 K | 0.97% |
|
Switzerland |
|
5 |
USD 356.37
|
Dec. 31, 2023 | USD 1.04 K | -2.38% |
|
Switzerland |
|
6 |
USD 348.71
|
Dec. 31, 2023 | USD 24.38 | 0.88% |
|
South Korea |
|
7 |
USD 150.85
|
Sept. 30, 2024 | USD 234.50 | 0.17% |
|
United States |
|
8 |
USD 139.08
|
Dec. 31, 2023 | USD 68.20 | 0.14% |
|
South Korea |
|
9 |
USD 128.63
|
Sept. 30, 2024 | USD 690.87 | -3.63% |
|
United States |
|
10 |
USD 110.55
|
Sept. 28, 2024 | USD 556.99 | 0.27% |
|
United States |
|
11 |
USD 109.46
|
Dec. 31, 2023 | USD 108.37 | -2.33% |
|
South Korea |
|
12 |
USD 108.80
|
Dec. 31, 2023 | USD 7.15 | 4.63% |
|
South Korea |
|
13 |
USD 108.35
|
Dec. 31, 2023 | USD 588.68 | -0.80% |
|
Switzerland |
|
14 |
USD 105.10
|
Nov. 30, 2023 | USD 11.35 | -0.53% |
|
United States |
|
15 |
USD 99.93
|
Dec. 31, 2023 | USD 244.50 | 0.95% |
|
Switzerland |
|
16 |
USD 90.81
|
Sept. 30, 2024 | USD 342.23 | -2.69% |
|
United States |
|
17 |
USD 84.38
|
Sept. 30, 2024 | USD 197.96 | -3.26% |
|
United States |
|
18 |
USD 78.97
|
Sept. 28, 2024 | USD 178.08 | -6.34% |
|
United States |
|
19 |
USD 64.71
|
Sept. 30, 2024 | USD 143.06 | -4.74% |
|
United States |
|
20 |
USD 60.58
|
Dec. 31, 2023 | USD 122.96 | -0.16% |
|
Ireland |
|
21 |
USD 60.47
|
Sept. 30, 2024 | USD 267.10 | -1.14% |
|
United States |
|
22 |
USD 60.24
|
Sept. 30, 2024 | USD 364.70 | 0.50% |
|
United States |
|
23 |
USD 57.73
|
Sept. 30, 2024 | USD 362.80 | 0.50% |
|
United States |
|
24 |
USD 57.47
|
Dec. 31, 2023 | USD 36.83 | -2.69% |
|
South Korea |
|
25 |
USD 53.52
|
Dec. 31, 2023 | USD 20.20 | -1.60% |
|
Germany |
|
26 |
USD 53.29
|
Dec. 31, 2023 | USD 145.16 | 0.75% |
|
Germany |
|
27 |
USD 51.26
|
Dec. 31, 2023 | USD 19.81 | 0.71% |
|
Belgium |
|
28 |
USD 50.30
|
Dec. 31, 2023 | USD 97.52 | 0.29% |
|
Switzerland |
|
29 |
USD 44.54
|
March 31, 2024 | USD 355.46 | -1.48% |
|
Switzerland |
|
30 |
USD 44.12
|
Dec. 31, 2023 | USD 122.64 | 0.35% |
|
France |
|
31 |
USD 43.42
|
Dec. 31, 2023 | USD 4.71 | 1.18% |
|
South Korea |
|
32 |
USD 42.30
|
Sept. 30, 2024 | USD 131.05 | -0.04% |
|
United States |
|
33 |
USD 41.99
|
Sept. 29, 2024 | USD 41.10 | -7.87% |
|
United States |
|
34 |
USD 41.88
|
Dec. 31, 2023 | USD 18.55 | -3.93% |
|
Germany |
|
35 |
USD 41.13
|
Sept. 30, 2024 | USD 411.66 | -0.41% |
|
United States |
|
36 |
USD 39.87
|
Dec. 31, 2023 | USD 698.37 | 1.93% |
|
South Korea |
|
37 |
USD 37.62
|
Sept. 30, 2024 | USD 1.78 | 4.71% |
|
United States |
|
38 |
USD 37.34
|
Dec. 31, 2023 | USD 216.88 | 1.28% |
|
Denmark |
|
39 |
USD 37.28
|
Dec. 31, 2023 | USD 47.49 | -5.41% |
|
Luxembourg |
|
40 |
USD 36.78
|
Dec. 31, 2023 | USD 1.83 | 0.74% |
|
South Korea |
|
41 |
USD 35.33
|
Dec. 31, 2023 | USD 10.34 | -1.02% |
|
South Korea |
|
42 |
USD 34.44
|
Dec. 31, 2023 | USD 49.86 | 0.81% |
|
Germany |
|
43 |
USD 34.33
|
Dec. 31, 2023 | USD 110.89 | -1.59% |
|
France |
|
44 |
USD 33.24
|
Dec. 31, 2023 | USD 208.18 | -0.28% |
|
France |
|
45 |
USD 31.41
|
Sept. 30, 2024 | USD 175.55 | -0.67% |
|
United States |
|
46 |
USD 31.24
|
Sept. 30, 2024 | USD 17.64 | -3.66% |
|
United States |
|
47 |
USD 30.56
|
Dec. 31, 2023 | USD 195.15 | -0.39% |
|
Belgium |
|
48 |
USD 30.41
|
June 30, 2024 | USD 173.13 | 0.11% |
|
Australia |
|
49 |
USD 29.31
|
Dec. 31, 2023 | USD 129.77 | -1.69% |
|
United Kingdom |
|
50 |
USD 29.18
|
Sept. 30, 2024 | USD 158.62 | 1.47% |
|
United States |
The Biotechnology company with the highest Revenue Per Share is Cingulate Inc. (NasdaqCM: CING) at USD 68,343.25.
The Biotechnology company with the lowest Revenue Per Share is ESSA Pharma Inc. (NasdaqCM: EPIX) at USD 0.00.
The top 10 Biotechnology companies the Global by Revenue Per Share are Cingulate Inc., Eurofins-Cerep SA, Sunshine Biopharma, Inc., Metall Zug AG, Siegfried Holding AG, SK Discovery Co., Ltd., Laboratory Corporation of America Holdings, Dong-A Socio Holdings Co., Ltd., Regeneron Pharmaceuticals, Inc. and Thermo Fisher Scientific Inc..
The bottom 10 Biotechnology companies by Revenue Per Share are ESSA Pharma Inc., Vera Therapeutics, Inc., Eupraxia Pharmaceuticals Inc., NFL Biosciences SA, TWi Biotechnology, Inc., Outlook Therapeutics, Inc., Ovoca Bio plc, Ultimovacs ASA, Alpha Tau Medical Ltd. and Cantargia AB (publ).